In­flaRx wins FDA emer­gency use au­tho­riza­tion for Covid an­ti­body

In­flaRx’s mon­o­clon­al an­ti­body vilo­be­limab has re­ceived emer­gency use au­tho­riza­tion to treat crit­i­cal­ly ill Covid-19 pa­tients on in­va­sive me­chan­i­cal ven­ti­la­tion.

Vilo­be­limab, which will be sold un­der the brand name Go­hibic, was cleared for use in hos­pi­tal­ized adults with­in 48 hours of re­ceiv­ing in­va­sive me­chan­i­cal ven­ti­la­tion or ex­tra­cor­po­re­al mem­brane oxy­gena­tion, ac­cord­ing to In­flaRx. The Ger­man biotech said it’s ramp­ing up pro­duc­tion and will roll out the drug as soon as pos­si­ble.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN